PPT-ADNI 3 plans for Biomarker Core

Leslie M Shaw amp John Q Trojanowski Magdalena Korecka Michal Figurski Teresa Waligorska Magdalena Brylska Leona Fields Nirali Shah Biomarker Core Aims for ADNI 3 Continue to collect store curate and track all . MBBS (Hons), . MMedSci. (. Clin. . Epid. ), . MBiostat. , PhD, FRACP. Biomarker-Based Clinical Trials: Practical and Design Considerations. Biomarker. “Any characteristic that can be objectively measured as an indicator of normal or pathological biological processes or the response to a therapy”. Andy Saykin. WW-ADNI Meeting. London, UK. July 14, 2017. asaykin@iupui.edu. Overview and 2017 Updates. ADNI-3 sample collection (banked at NCRAD). Longitudinal DNA & RNA (12 new, 79 continuing). Changes in ADNI-3 include PBMC and RBC collection. AAIC 2017. Presenter: Dr. Patricio . Chrem. . On . Behalf of:. Dr. Prof Ricardo Allegri (PI) . Dr. Gustavo Sevlever. July 14. th. , 2017. Arg. -ADNI. Patients’ Flowchart. Patients Screened at FLENI. . SYFTET. Göteborgs universitet ska skapa en modern, lättanvänd och . effektiv webbmiljö med fokus på användarnas förväntningar.. 1. ETT UNIVERSITET – EN GEMENSAM WEBB. Innehåll som är intressant för de prioriterade målgrupperna samlas på ett ställe till exempel:. Update. Veronika. . Logovinsky. , MD, PhD. . 2017 . Chairperson . WW ADNI Meeting. July . 14, 2017. PPSB: Leadership. Chair. N/A. Chair-elect. Veronika . Logovinsky. , Eisai. FNIH. Michael Biarnes, Scientific Project Manager* . Initiative . December, 2010. NEED FOR VALIDATED BIOMARKERS FOR AD TRIALS. Biomarkers useful in Phase 2 to make decisions about Phase 3 (e.g. doses). Biomarkers useful in Phase 3. Provide additional evidence to support primary outcome findings. a measurable indicator . that . can . tell . us something about a person’s health or disease . state, for example, . disease (pathological) processes in the body, for example, disease stage. , . biological processes in the body (heart rate, blood pressure, temperature), . Boston, MA 4/24/2017 . Leslie M Shaw. John Q Trojanowski. New biomarkers in NIA/ADNI/RARC-approved studies . Biomarker. Fluid. #. ADNI study. Investigator. NFL & Tau . diag. /prognosis. Plasma. 3,000+. Mayo. . Cliff Jack. Bret Borowski . Matt Bernstein. Arvin Forghanian-Arani . Jeff Gunter. Dave Jones . Kejal Kantarci. Rob Reid . Denise Reyes . Matt Senjem. Kaely Thostenson. Prashanthi Vemuri . Chad Ward . PhUSE 2014 Paper SP06 Renuka Chinthapally, Cytel Statistical Software & Services Pvt. Ltd., Hyderabad, India ABSTRACT Biomarkers play an important role in the clinical development due to their ability 2 Understanding the biomarker research activity, is critical as multiple stakeholders align themselves with the latest science. CONTENTSFOREWORDBy Edward Abrahams, President, Personalized Medicine Coa Bret Borowski . Matt Bernstein. Arvin Forghanian-Arani . Jeff Gunter. Dave Jones . Kejal Kantarci. Rob Reid . Denise Reyes . Matt Senjem. Kaely Thostenson. Prashanthi Vemuri . Chad Ward . Funded MRI Investigators. Limitations of . Circulating miRNA. Performed by the . Data Management . a. nd Resource Repository (DMRR). ERCC . D. ata Analysis. 1. Williams Z., et al. . (. 2013. ) Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations. Cliff Jack. Bret Borowski . Matt Bernstein. Arvin Forghanian-Arani . Jeff Gunter. Dave Jones . Kejal Kantarci. Rob Reid . Denise Reyes . Matt Senjem. Kaely Thostenson. Prashanthi Vemuri . Chad Ward .